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Abstract
Purpose: This brief report describes a planned, interim, 6-patient toxicity analysis that conﬁ  rms the safety of pemetrexed, 
carboplatin, radiation with subsequent surgery, as prescribed in the North Central Cancer Treatment Group trial N044E, in 
patients with locally advanced esophageal cancer.
Methods: Six patients with locally advanced, potentially resectable esophageal cancer received pemetrexed 500 mg/m² and 
carboplatin AUC = 6 on days 1 and 22 with 5040 centigray of concomitant radiation in 28 fractions over 5.5 weeks followed 
by esophagectomy as a prelude to a phase II multi-institutional trial.
Results: Only 1 of the 6 patients experienced a grade 4 adverse event (neutropenia). This patient also experienced a grade 
3 depression. Of the remaining 5 patients, three experienced at least one grade 3 adverse event (neutropenia, nausea/vomit-
ing, and esophagitis). There were no deaths. Incidentally, one patient manifested a complete pathologic response, three a 
partial pathologic response, and one stable disease.
Conclusion: These preliminary observations on safety suggest that this regimen can be further studied in this clinical setting.
Despite aggressive therapy with chemotherapy, radiation, and subsequent surgery, most patients with 
locally advanced esophageal cancer ultimately die from their disease [1]. This sobering outcome points 
to a clear need to begin to deﬁ  ne cancer treatment strategies that are well tolerated and that nonetheless 
yield favorable clinical outcomes.
In view of this unmet need, a recent study from Siewert and others appears particularly intriguing 
[2]. These investigators reported on a phase I study with the novel, promising combination of peme-
trexed, carboplatin, and radiation. The former is a multitargeted antifolate and preclinical and early 
clinical studies suggest this agent carries activity in patients with gastrointestinal malignancies, most 
relevantly, gastric cancer [3]. Of note, although Siewert and others found that this regimen was well 
tolerated, none of the esophageal cancer patients in this study was treated at the recommended maxi-
mally tolerated dose of pemetrexed 500 mg/m², carboplatin AUC = 6, concurrently with radiation. Thus, 
this brief report provides the critically needed tolerability proﬁ  le of this trimodality, neoadjuvant approach 
to enable investigators to further evaluate this combination in this setting.
Methods
Overview
The Mayo Clinic Institutional Review Board approved the study protocol before patient enrollment, 
and all patients provided signed informed consent.224
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Patient eligibility and exclusion criteria
Salient eligibility criteria for the trial included 
the following: 1) age 18 years; 2) potentially 
resectable squamous cell cancer or adenocarcinoma 
of the esophagus or gastroesophageal junction 
(patients with celiac or supraclavicular node 
involvement were eligible depending on the loca-
tion of the primary tumor, and patients with 
T1N0M0 and T2N0M0 tumors were not eligible); 
3) able to receive radiation, 4) Eastern Cooperative 
Oncology Group performance score of 2 or bet-
ter; 5) a pretreatment absolute neutrophil count 
of 1500/mL, platelet count of 100,000/mL, 
hemoglobin 10 g/dL, total bilirubin 1.5 × the 
upper limit of normal, aspartate transaminase 
3 × the upper limit of normal, and a calculated 
creatinine clearance 45 mL/minute; and 6) able 
to discontinue non-steroidal anti-inﬂ  ammatory 
agents, as outlined in the pemetrexed package 
insert.
Similarly, notable exclusion criteria included 
the following: 1) pregnancy or unwillingness to 
utilize contraception if pregnancy is a possibility; 
2) illness or infection that would make the patient 
unable to tolerate study treatment; 3) prior radiation 
that would overlap anticipated radiation ﬁ  elds 
or radiation to 30% of the marrow cavity; 4) prior 
chemotherapy for esophageal cancer; 5) prior 
malignancy in the preceding 5 years with a notable 
risk for metastatic potential; or 6) previous reaction 
to pemetrexed or carboplatin.
Pretreatment, treatment,
and follow-up
All patients underwent a pretreatment history and 
physical examination as well as the testing needed 
to verify that they were meeting the eligibility crite-
ria. Patients were also required to have completed 
computerized tomography of the chest and abdomen, 
an esophagoscopy, and an electrocardiogram.
A bronchoscopy and/or a bone scan were recom-
mended in the event the treating oncologist had a 
clinical suspicion of high diagnostic yield. Endo-
scopic ultrasound was not mandated by the study 
protocol.
Patients were then monitored weekly through-
out the radiation and concurrent chemotherapy 
administration period with a history, physical 
examination, and twice-a-week hemogram. Prior 
to the administration of chemotherapy, a chemistry 
proﬁ  le was also required.
Tumor assessments were performed prior to 
surgery with the RECIST criteria [4]. Post-
operatively, patients were assessed for pathologic 
response.
Chemotherapy, radiation,
and surgery
Chemotherapy consisted of pemetrexed 500 mg/m² 
intravenously and carboplatin with an area under 
curve (AUC) of 6 intravenously on days 1 and 22. 
All patients were prescribed folic acid and vitamin 
B12 starting seven or more days prior to protocol 
treatment, as per the pemetrexed package insert. 
Chemotherapy dose reductions on day 22 were 
speciﬁ  ed in the protocol and required that chemo-
therapy either be held, dose-reduced, or completely 
discontinued based on type and severity of adverse 
event.
Radiation was prescribed at a total dose of 5040 
centigray with 180 centigray per fraction for a total 
of 28 fractions over 5.5 weeks. Treatment was to 
be held in the event of an absolute neutrophil count 
of 1000/mL or a platelet count of 50,000/mL.
An esophagectomy was to be performed within 
4–12 weeks after completion of the concurrent 
chemotherapy and radiation.
Analyses
This report describes a planned safety analysis of 
the ﬁ  rst 6 consecutive patients enrolled on a phase 
II trial. It was decided a priori that if none of the 
6 patients suffered a treatment-related grade 5 
adverse event from the time of study initiation to 
1-month post-surgery, the remaining cohort would 
be enrolled.
Unless otherwise speciﬁ  ed, all adverse events 
are reported regardless of attribution to study treat-
ment.
Results
Demographics
Demographics for these ﬁ  rst 6 patients are shown in 
Table 1. Of the 6 patients 5 were male, and the 
median age of the cohort was 67 years (range 52–75). 
Five patients had an Eastern Cooperative Oncology 
Group Performance score of 0, and one had a score 
of 1. All patients had tumors of adenocarcinoma 
histology.225
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Treatment administration
All 6 patients received full-dose pemetrexed and 
carboplatin during the ﬁ  rst cycle. During the sec-
ond cycle, however, adverse events prompted 3 of 
6 patients to receive chemotherapy dose reductions. 
Two patients received approximately half the dose 
prescribed in the ﬁ  rst cycle, and one received 
roughly 75%.
All patients completed all their intended radia-
tion, and all underwent surgery. One patient’s 
surgery was delayed by one week beyond the inter-
val speciﬁ  ed in the protocol for medical reasons.
Adverse events
Only 1 of the 6 patients experienced a grade 4 
adverse event, which consisted of neutropenia. 
This patient also experienced a grade 3 depression. 
Of the remaining 5 patients, three experienced at 
least one grade 3 adverse event (neutropenia, nau-
sea, vomiting, and esophagitis). There were no 
deaths, and all patients were carefully evaluated 
for vital status post-operatively (Table 2). All 
adverse events of grade 3 or worse occurred during 
or shortly after neoadjuvant therapy. No severe 
post-operative adverse events occurred.
Response data
One patient had a complete pathological response, 
3 had a partial pathological response, and one had 
stable disease.
Discussion
This report describes the results of a planned 
interim toxicity analysis that focused on the ﬁ  rst 
6 patients enrolled on a multi-institutional trial for 
patients with locally advanced esophageal cancer. 
The combination of pemetrexed and carboplatin, 
as prescribed here, in conjunction with concomi-
tant radiation and followed by surgery is well 
tolerated and appears to merit further study in this 
setting.
Although this brief report encompasses only 6 
patients, the adverse event data described here are 
necessary to permit the further study of this regi-
men in patients with locally advanced esophageal 
cancer. Previous studies have demonstrated that 
some regimens offer limited survival beneﬁ  ts while 
providing a substantial adverse event profile, 
including hospitalization rates that exceed 50%, 
grade 3 or 4 adverse event rates that go beyond 
70%, and treatment-related death rates that occur 
in over 5% of patients [5]. Therefore, reporting 
preliminary safety data for a promising regimen, 
as summarized in this brief report, provides the 
necessary groundwork for further study of such a 
regimen, especially when the requisite phase I data 
are lacking.
Thus, based on the data presented here, the 
North Central Cancer Treatment Group is proceed-
ing with a multi-institutional phase II trial that tests 
the foregoing regimen in patients with locally 
advanced esophageal cancer.
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Table 2. Grade 3 or worse maximal adverse events 
(N = 6)*.
Adverse event  Number of patients
neutropenia 2
depression 1
nausea/vomiting 1
esophagitis 1
*Other events such as anemia, thrombocytopenia, neuropathy, diar-
rhea, and dehydration were solicited but not detected.
Table 1. Patient demographics (n = 6)*.
Age in years
 median  (range)  67  (52–75)
Male: Female  5:1
Eastern Cooperative Oncology
Group performance score
 0  5
 1  1
*Numbers denote number of patients unless otherwise speciﬁ  ed.